PRDM14 siRNA therapy (AccuRna/University of Tokyo)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NamePRDM14 siRNA therapy (AccuRna/University of Tokyo)
Drug Alias NamePRDM14 siRNA therapy (AccuRna/University of Tokyo/NanoCarrier)SRN-14/GL2-800
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNASmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionPR Domain Zinc Finger Protein 14 inhibitors
TargetsPR Domain Zinc Finger Protein 14
Therapy Area/IndicationsMetastatic breast cancerBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAccuRna Inc
China Registration ClassN/A

Develop Information

Active CompaniesAccuRna IncNANO MRNA Co LtdUniversity Of Tokyo
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancer
Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A